Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

HER4/ErbB4 is a ubiquitously expressed member of the EGF/ErbB family of receptor tyrosine kinases that is essential for normal development of the heart, nervous system, and mammary gland. We report here crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms. Active ErbB4 kinase adopts an asymmetric dimer conformation essentially identical to that observed to be important for activation of the EGF receptor/ErbB1 kinase. Mutagenesis studies of intact ErbB4 in Ba/F3 cells confirm the importance of this asymmetric dimer for activation of intact ErbB4. Lapatinib binds to an inactive form of the ErbB4 kinase in a mode equivalent to its interaction with the EGF receptor. All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. These results demonstrate that key elements of kinase activation and inhibition are conserved among ErbB family members.

[1]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[2]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[3]  G N Murshudov,et al.  Use of TLS parameters to model anisotropic displacements in macromolecular refinement. , 2001, Acta crystallographica. Section D, Biological crystallography.

[4]  N. Hynes,et al.  ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.

[5]  John Kuriyan,et al.  A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain , 2006, PLoS biology.

[6]  A. Ullrich,et al.  Intermolecular transphosphorylation between insulin receptors and EGF‐insulin receptor chimerae. , 1989, The EMBO journal.

[7]  M. Lemmon,et al.  Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.

[8]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[9]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[10]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[11]  M. Lawrence,et al.  Shape complementarity at protein/protein interfaces. , 1993, Journal of molecular biology.

[12]  K. Lackey,et al.  Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. , 2006, Bioorganic & medicinal chemistry letters.

[13]  M. Karamouzis,et al.  Breast cancer: the upgraded role of HER-3 and HER-4. , 2007, The international journal of biochemistry & cell biology.

[14]  M. Lemmon,et al.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface , 2004, FEBS letters.

[15]  H. Kim,et al.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. , 1997, The Biochemical journal.

[16]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[17]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Samuel Bouyain,et al.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[20]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[21]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[22]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[23]  Christopher P Mill,et al.  Inter-conversion of neuregulin2 full and partial agonists for ErbB4. , 2007, Biochemical and biophysical research communications.

[24]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[25]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[26]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[27]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[28]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[29]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[30]  G. Carpenter,et al.  ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.

[31]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[32]  Ron Bose,et al.  Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface , 2007, Nature.

[33]  A. Ullrich,et al.  Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation. , 1990, The Journal of biological chemistry.

[34]  W. Denny.  The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. , 2001, Farmaco.

[35]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[36]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[37]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Stern,et al.  Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[40]  Y. Yarden,et al.  ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.

[41]  A. M. Stanley,et al.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.

[42]  K. Lackey,et al.  Comparison of the Biochemical and Kinetic Properties of the Type 1 Receptor Tyrosine Kinase Intracellular Domains , 2002, The Journal of Biological Chemistry.

[43]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.